Page 3 - Dr Lal Pathlabs

Dr Lal PathLabs Q1 net profit dips 57% to Rs 58 cr; revenue falls 17%

Diagnostic services provider Dr Lal Path Labs on Thursday said its consolidated net profit declined 57 per cent to Rs 58 crore for the first quarter ended June 30

Covid-19: Analysts dump diagnostic firms for multiplexes on solid outlook

Experts believe the current news cycle may keep the stock prices of related players volatile in the near term, but any fundamental or direct impact, in the long run, remains improbable.

Trading strategies for Thyrocare, Dr Lal Path, Metropolis amid Covid scare

Thyrocare, Dr Lal Path Labs and Metropolis are trading almost 50 per cent below their respective all-time highs, the reversal may see breakout if the key respective levels are sustained

Near-term outlook prescription for diagnostic firms looks fragile

Competitive pressures, high valuations limit upsides for listed lab chains

We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country

Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21

Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line

Dr Lal PathLabs unveils pilot project to transport blood samples via drones

Diagnostic services provider Dr Lal PathLabs on Tuesday said it has launched a pilot project to use drones for transporting blood samples. The use of drones would expand Dr Lal Pathlab's services to inaccessible locations, the company said in a statement. Pilot projects are being launched across multiple remote, semi-urban and rural locations to experiment multiple-use cases that eliminate challenges like congestion due to traffic, poor road conditions and inaccessibility, it added. "As the leader in diagnostic industry, Dr Lal PathLabs is committed towards integration of new technologies into its existing logistics systems to further expedite sample collections. The use of drones could significantly speed-up regular and emergency medical care in rural areas and help save lives," Dr Lal PathLabs Head Logistics & Home Collection Amit Aggarwal noted. The company is initiating pilot projects in different parts of the country. "If these first trial runs are successful, we are hopeful

Diagnostics chain Dr Lal PathLabs posts Rs 58 crore profit for Dec quarter

Diagnostics chain Dr Lal PathLabs Ltd on Thursday reported a consolidated net profit of Rs 58.2 crore in the third quarter ended in December 2021. The company had posted a consolidated net profit of Rs 95.9 crore in the same quarter last fiscal, Dr Lal PathLabs said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 496.9 crore. It was at Rs 452.4 crore in the year-ago period, it added. The results include that of Suburban Diagnostics with effect from November 12, 2021, and hence is not strictly comparable with previous year, the company said. Covid and allied contributed 11.8 per cent to revenue in Q3 FY22 with 5.8 lakh RTPCR tests, it added. Total expenses during the third quarter were at Rs 427.5 crore, up from Rs 337 crore in the year-ago quarter, Dr Lal PathLabs said.

We entered an otherwise hard market with Suburban deal: Dr Lal Pathlabs MD

In a Q&A, Om Manchanda says the firm is now growing organically in the Southern market, but is open to inorganic opportunities there

Dr Lal PathLabs Q2 net up 11% at Rs 96 cr; to acquire Suburban Diagnostics

Diagnostic services provider Dr Lal PathLabs on Tuesday posted a 10.6 per cent increase in its consolidated profit after tax (PAT) at Rs 96.3 crore for the second quarter ended September 30

Thyrocare, Lal Pathlabs: Diagnostic stocks trade weak. Should you worry?

Given the weakness seen on Monday, should you be worried regarding stocks from this sector? Here is how they look on the charts

Stock picks by Sameet Chavan: Buy ITC, sell Dr Lal PathLabs

Dr Lal PathLabs' stock seems to have lost its sheen now as we are seeing consistent corrective moves over the past few weeks

Top trading ideas by Mehul Kothari of Anand Rathi: Buy HEG, L&T

HEG stock after trading with a strong uptrend recently underwent some consolidation

Near-term margin concerns and valuations weigh on Dr Lal Pathlabs

Some brokerages prefer Metropolis given higher realisation, revenue growth trajectory

Bet on these diagnostic stocks for up to 19% return as Covid-19 cases flare

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Dr Lal PathLabs hits record high in a weak market; surges 19% in 5 days

The company would continue to reap benefits from increased Covid-related and allied testing in its widespread network of diagnostic centers and labs, analysts believe

Sales recovery, expansion in new markets key to Dr Lal Pathlabs' growth

Higher competition, expansion may be a challenge for margin

Nifty outlook & trading strategies by CapitalVia: Buy SBI, Dr Lal PathLabs

Better-than-expected Q2 GDP data numbers might help index to move in the positive territory

Dr Lal PathLabs, Thyrocare slip on profit booking on Covid vaccine optimism

From March lows, the stock price of Thyrocare Technologies has been more-than-tripled and of Dr Lal PathLabs more-than-doubled on the BSE